keyword
MENU ▼
Read by QxMD icon Read
search

Cardiovascular risk HIV

keyword
https://www.readbyqxmd.com/read/28443391/atazanavir-sulfate-cobicistat-for-the-treatment-of-hiv-infection
#1
Francisco Antunes
The life expectancy of patients living with HIV has increased significantly in the last two decades, as a result of the great progress in treatment of HIV infection. During this time, several drugs were developed to offer long-term benefits in terms of virologic efficacy, favourable tolerability and toxicity profiles. Pharmacokinetic boosting of protease inhibitors allows a higher genetic barrier, as few or no drug-resistant mutations are detected in patients with virologic failure. Areas covered: Atazanavir sulfate + cobicistat (ATV/c) was recently approved in the United States of America and in the European Union for the treatment of HIV-1 infection...
April 26, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28438737/association-of-tenofovir-use-with-risk-of-incident-heart-failure-in-hiv-infected-patients
#2
Ruijun Chen, Rebecca Scherzer, Priscilla Y Hsue, Vasantha Jotwani, Michelle M Estrella, Michael A Horberg, Carl Grunfeld, Michael G Shlipak
BACKGROUND: The antiretroviral medication, tenofovir disoproxil fumarate (TDF), is used by most human immunodeficiency virus-infected persons in the United States despite higher risks of chronic kidney disease. Although chronic kidney disease is a strong risk factor for heart failure (HF), the association of TDF with incident HF is unclear. METHODS AND RESULTS: We identified 21 435 human immunodeficiency virus-infected patients in the United States Veterans Health Administration actively using antiretrovirals between 2002 and 2011...
April 24, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#3
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28427339/cardiovascular-disease-risk-among-chinese-antiretroviral-na%C3%A3-ve-adults-with-advanced-hiv-disease
#4
Fuping Guo, Evelyn Hsieh, Wei Lv, Yang Han, Jing Xie, Yanling Li, Xiaojing Song, Taisheng Li
BACKGROUND: Cardiovascular disease (CVD) is an important cause of mortality among HIV-infected patients, however little is known about the burden of CVD among this population in Asia. We sought to quantify prevalence of CVD risk factors, 10-year CVD risk, and patterns of CVD risk factor treatment in a group of individuals with HIV in China. METHODS: We retrospectively analyzed baseline data from treatment-naïve HIV-infected adults enrolled in two multicenter clinical trials in China...
April 20, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28426535/frailty-in-hiv-infected-people-a-new-risk-factor-for-bone-mineral-density-loss
#5
Sylvie Bregigeon, Anne Galinier, Olivia Zaegel-Faucher, Carla E Cano, Véronique Obry, Hélène Laroche, Sophie Trijau, Armelle Saout, Isabelle Poizot-Martin
OBJECTIVE: This study aims to assess the association between bone mineral density (BMD) and frailty in a cohort of HIV-infected patients. DESIGN: A cross-sectional study in an HIV outpatient unit where nearly 1,000 patients are monitored. METHODS: Subjects undergoing bone densitometry were proposed an evaluation of frailty using criteria of the Cardiovascular Health Study (CHS) and the Study of Osteoporotic Fractures (SOF). Frailty markers (FM) were weight-loss, self-reported exhaustion, physical activity, grip strength, chair stands, and slow gait...
April 19, 2017: AIDS
https://www.readbyqxmd.com/read/28424436/-dyslipidemia-and-cardiovascular-risk-assessment-in-hiv-positive-patients
#6
Serhat Uysal, Mürşide Tuncel Başoğlu, Bahar Boydak, Deniz Gökengin
OBJECTIVE: Dyslipidemia is a major complication of antiretroviral treatment. Aim of the present study was to screen baseline lipid levels and cardiovascular disease risk in HIV-positive patients and analyze change in those parameters after initiation of antiretroviral treatment (ART). METHODS: HIV-positive patients who presented at our clinic between April 2011 and August 2012 were included. Study included 19 female (22.1%) and 67 male (77.9%) patients (mean age 39...
March 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28422809/associations-between-dietary-intake-prior-to-6-months-of-age-and-rapid-weight-gain-among-hiv-exposed-uninfected-infants
#7
Daniela Neri, Fernanda C Oliveira, Aline M Carvalho, Gabriel A Somarriba, Gwendolyn B Scott, Tracie L Miller
INTRODUCTION: HIV-exposed, uninfected (HEU) infants are potentially at risk for cardiovascular disease due to in utero exposures. Feeding practices of the infant could compound this risk. However, few studies have evaluated dietary intake of HEU infants. We determined dietary factors associated with rapid weight gain (RWG) among HEU infants from birth to 6 months followed at the University of Miami HIV Screening Program. METHODS: In this cross-sectional analysis, logistic regression was used to determine dietary factors associated with RWG defined as a greater than 0...
April 18, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28416296/hiv-infection-and-aortic-stiffness
#8
REVIEW
Luisa Helena Maia Leite, Ariel Cohen, Franck Boccara
People living with human immunodeficiency virus (HIV) infection and receiving antiretroviral therapy now have the same life expectancy as the general population. However, they have a higher risk of atherosclerotic cardiovascular events because of a complex and polyfactorial vasculopathy, combining the effects of antiretroviral therapy, the HIV virus itself, immune activation, chronic inflammation and metabolic disturbances. Whether people living with HIV infection experience increased vascular aging compared with the general population remains controversial...
April 14, 2017: Archives of Cardiovascular Diseases
https://www.readbyqxmd.com/read/28416195/pitavastatin-versus-pravastatin-in-adults-with-hiv-1-infection-and-dyslipidaemia-intrepid-12-week-and-52-week-results-of-a-phase-4-multicentre-randomised-double-blind-superiority-trial
#9
Judith A Aberg, Craig A Sponseller, Douglas J Ward, Vladimir A Kryzhanovski, Stuart E Campbell, Melanie A Thompson
BACKGROUND: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia...
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28410829/metabolic-syndrome-among-hiv-infected-patients-a-comparative-cross-sectional-study-in-northwestern-nigeria
#10
Fakhraddeen Yahya Muhammad, Ibrahim Danjummai Gezawa, Andrew Uloko, Ahmad Maifada Yakasai, Abdulrazaq Garba Habib, Garba Iliyasu
INTRODUCTION: The increasing availability of antiretroviral drugs has made HIV-positive patients to live longer, and conditions that are associated with longevity such as metabolic syndrome and other cardiovascular related conditions have become relevant in them. This is less well studied among African populations. Therefore the study aimed at estimating and comparing the prevalence of and associated risk factors for the metabolic syndrome (MS) among African HIV infected patients. METHOD: In this comparative cross-sectional study, we analyzed the data of 300 participants matched for age and gender who satisfied the inclusion criteria with half of the subjects on HAART, while the other half was HAART naïve...
April 5, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/28409013/lay-beliefs-about-hypertension-among-hiv-infected-adults-in-kenya
#11
Tecla M Temu, Ehete Bahiru, Fredrick Bukachi, Gerald S Bloomfield, Peter Muiruri, Carey Farquhar
OBJECTIVE: Hypertension affects 23% of Kenyans and is the most prevalent modifiable risk factor for cardiovascular disease. Despite this, hypertension awareness and treatment adherence is very low. We conducted a qualitative study to explore lay beliefs about hypertension among HIV-infected adults to inform the development of culture sensitive hypertension prevention and control program. METHODS: Eight focus group discussions were held for 53 HIV-infected adults at the HIV clinic in Kenya...
2017: Open Heart
https://www.readbyqxmd.com/read/28398958/new-onset-diabetes-in-hiv-treated-adults-from-thailand-predictors-long-term-renal-and-cardiovascular-outcomes
#12
Opass Putcharoen, Lalita Wattanachanya, Jiratchaya Sophonphan, Sarawut Siwamogsatham, Vorapot Sapsirisavat, Sivaporn Gatechompol, Supalak Phonphithak, Stephen J Kerr, Yingyos Avihingsanon, Kiat Ruxrungtham, Anchalee Avihingsanon
OBJECTIVE: To determine the incidence and risk factors for developing diabetes mellitus (DM) in a cohort of Thai HIV-infected patients on long-term combination antiretroviral therapy (cART). DESIGN: Prospective study conducted between July 1996-April 30, 2015. METHODS: 1,748 subjects (60% males) who did not have DM prior to ART were assessed twice a year. Incident DM was defined as either having two consecutive fasting glucose levels >126 mg/dL, or reporting anti-DM medication/ DM diagnosis after starting cART...
April 10, 2017: AIDS
https://www.readbyqxmd.com/read/28397248/porphyromonas-gingivalis-antibody-levels-and-diagnosis-of-coronary-artery-disease-in-hiv-positive-individuals
#13
V L Berquist, A C Hearps, P Ford, A Jaworowski, S J Leishman, J F Hoy, J M Trevillyan
BACKGROUND AND OBJECTIVE: Periodontal disease has been associated with cardiovascular disease in the general population. It is unknown whether IgG antibody levels for periodontal pathogens are associated with the diagnosis of coronary artery disease (CAD) in HIV-positive individuals. MATERIAL AND METHODS: Twenty-four HIV-positive individuals (cases) with stored plasma available in the 12 months before CAD diagnosis were age- and sex-matched 1:2 with 46 HIV-positive individuals without CAD (controls)...
April 10, 2017: Journal of Periodontal Research
https://www.readbyqxmd.com/read/28391912/effects-of-atorvastatin-on-biomarkers-of-immune-activation-inflammation-and-lipids-in-virologically-suppressed-human-immunodeficiency-virus-1-infected-individuals-with-low-density-lipoprotein-cholesterol-130%C3%A2-mg-dl-aids-clinical-trials-group-study-a5275
#14
Daniel E Nixon, Ronald J Bosch, Ellen S Chan, Nicholas T Funderburg, Sally Hodder, Jordan E Lake, Michael M Lederman, Karin L Klingman, Judith A Aberg
BACKGROUND: Persistent immune activation and inflammation in virologically suppressed human immunodeficiency virus (HIV) infection are linked to excess cardiovascular risk. OBJECTIVE: To evaluate atorvastatin as a strategy to reduce cardiovascular risk. METHODS: A5275 was a multicenter, prospective, randomized, double-blind, placebo-controlled, cross-over pilot study of atorvastatin (10 mg/day for 4 weeks then 20 mg/day for 16 weeks) with a planned enrollment of 97 HIV-infected participants ≥18 years old, receiving boosted protease inhibitor-based antiretroviral therapy for ≥6 months, with plasma HIV-1 RNAs below limits of quantification ≥180 days, and fasting low-density lipoprotein (LDL) cholesterol ≥70 and <130 mg/dL...
January 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28384660/association-between-hiv-infection-and-the-risk-of-heart-failure-with-reduced-ejection-fraction-and-preserved-ejection-fraction-in-the-antiretroviral-therapy-era-results-from-the-veterans-aging-cohort-study
#15
Matthew S Freiberg, Chung-Chou H Chang, Melissa Skanderson, Olga V Patterson, Scott L DuVall, Cynthia A Brandt, Kaku A So-Armah, Ramachandran S Vasan, Kris Ann Oursler, John Gottdiener, Stephen Gottlieb, David Leaf, Maria Rodriguez-Barradas, Russell P Tracy, Cynthia L Gibert, David Rimland, Roger J Bedimo, Sheldon T Brown, Matthew Bidwell Goetz, Alberta Warner, Kristina Crothers, Hilary A Tindle, Charles Alcorn, Justin M Bachmann, Amy C Justice, Adeel A Butt
Importance: With improved survival, heart failure (HF) has become a major complication for individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends to different types of HF in the antiretroviral therapy (ART) era. Determining whether HIV infection is associated with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or both is critical because HF types differ with respect to underlying mechanism, treatment, and prognosis...
April 5, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28379043/hiv-and-risk-of-cardiovascular-disease-in-sub-saharan-africa-rationale-and-design-of-the-ndlovu-cohort-study
#16
Alinda Vos, Hugo Tempelman, Walter Devillé, Roos Barth, Annemarie Wensing, Mirjam Kretzschmar, Kerstin Klipstein-Grobusch, Andy Hoepelman, Kiki Tesselaar, Sue Aitken, Mashudu Madzivhandila, Cuno Uiterwaal, Francois Venter, Roel Coutinho, Diederick E Grobbee
Background The largest proportion of people living with HIV resides in sub-Saharan Africa (SSA). Evidence from developed countries suggests that HIV infection increases the relative risk of cardiovascular disease (CVD) by up to 50%. Differences in lifestyle, gender distribution, routes of HIV transmission and HIV subtype preclude generalisation of data from Western countries to the SSA situation. The Ndlovu Cohort Study aims to provide insight into the burden of cardiovascular risk factors and disease, the mechanisms driving CVD risk and the contribution of HIV infection and its treatment to the development of CVD in a rural area of SSA...
January 1, 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28367026/comparison-of-calculated-versus-directly-measured-low-density-lipoprotein-cholesterol-an-evaluation-of-ten-formulas-for-an-hiv-positive-population-in-sub-saharan-africa
#17
Ifeyinwa Osegbe, Martin Ugonabo, Chinwe Chukwuka, Ijeoma Meka, Nnamdi Nwosu
BACKGROUND: Low-density lipoprotein cholesterol (LDLC) is a modifiable risk factor for atherosclerotic cardiovascular disease, therefore needs to be assessed and monitored. Direct homogeneous assays and various formulas exist to determine LDLC. We aimed to compare the directly measured LDL (dLDLC) with ten formulas for estimating LDLC. MATERIALS AND METHODS: This was a 2-year retrospective study of fasting lipid profile results obtained from HIV-positive patients attending an outpatient clinic at the University of Nigeria Teaching Hospital, Enugu, Nigeria, using homogeneous direct assays...
April 2017: Journal of Laboratory Physicians
https://www.readbyqxmd.com/read/28364370/recommendations-for-managing-drug-drug-interactions-with-statins-and-hiv-medications
#18
REVIEW
Barbara S Wiggins, Donald G Lamprecht, Robert L Page, Joseph J Saseen
The discovery of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) has enabled individuals to live longer. As a result, HIV is now often considered a chronic condition. However, as a result of the increase in longevity or the HIV treatment modalities themselves, individuals with HIV are at high risk for the development of atherosclerotic cardiovascular disease. Therefore, these patients should be optimized with pharmacologic therapy to lower their cardiovascular risk through the addition of statin therapy to their regimen...
April 1, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/28356058/hiv-infected-persons-with-type-2-diabetes-show-evidence-of-endothelial-dysfunction-and-increased-inflammation
#19
Malene Hove-Skovsgaard, Julie Christine Gaardbo, Lilian Kolte, Kamilla Winding, Ingebjørg Seljeflot, Asbjørn Svardal, Rolf Kristian Berge, Jan Gerstoft, Henrik Ullum, Marius Trøseid, Susanne Dam Nielsen
BACKGROUND: Increased incidence of cardiovascular diseases (CVD) in both HIV infection and type 2 diabetes (T2D) compared to the general population has been described. Little is known about the combined effect of HIV infection and T2D on inflammation and endothelial function, both of which may contribute to elevated risk of CVD. METHODS: Cross-sectional study including 50 HIV-infected persons on combination anti-retroviral therapy (cART), with HIV RNA <200 copies/mL (n = 25 with T2D (HIV + T2D+), n = 25 without T2D (HIV + T2D-)) and 50 uninfected persons (n = 22 with T2D (HIV-T2D+) and n = 28 without T2D (HIV-T2D-))...
March 29, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28353539/coronary-artery-endothelial-dysfunction-is-present-in-hiv-positive-individuals-without-significant-coronary-artery-disease
#20
Micaela Iantorno, Michael Schär, Sahar Soleimanifard, Todd T Brown, Richard Moore, Patricia Barditch-Crovo, Matthias Stuber, Shenghan Lai, Gary Gerstenblith, Robert G Weiss, Allison G Hays
OBJECTIVE: HIV+ individuals experience an increased burden of coronary artery disease (CAD) not adequately accounted for by traditional CAD risk factors. Coronary endothelial function (CEF), a barometer of vascular health, is depressed early in atherosclerosis and predicts future events but has not been studied in HIV+ individuals. We tested whether CEF is impaired in HIV+ subjects without CAD as compared to an HIV- population matched for cardiac risk factors. DESIGN/METHODS: In this observational study, CEF was measured noninvasively by quantifying isometric handgrip exercise (IHE)-induced changes in coronary vasoreactivity with MRI in 18 participants with HIV but no CAD (HIV+CAD-, based on prior imaging), 36 age- and cardiac risk factor-matched healthy participants with neither HIV nor CAD (HIV-CAD-), 41 subjects with no HIV but with known CAD (HIV-CAD+) and 17 subjects with both HIV and CAD (HIV+CAD+)...
March 28, 2017: AIDS
keyword
keyword
60597
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"